The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Mooi, J.K. ; Wirapati, P. ; Asher, R. ; Lee, C.K. ; Savas, P. ; Price, T.J. ; Townsend, A. ; Hardingham, J. ; Buchanan, D. ; Williams, D. ; Tejpar, S. ; Mariadason, J.M. ; Tebbutt, N.C.

Annals of oncology, 2018-11, Vol.29 (11), p.2240-2246 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível